

To,
**Head, Listing Compliance Department,
National Stock Exchange of India Limited**
Exchange Plaza, Plot No. C/1. G Block,
Bandra – Kurla Complex, Bandra (East),
Mumbai – 400 051
Scrip Symbol: METROPOLIS

Sub: Clarification to NSE Query

Dear Sir/ Madam,

This is with reference to your email dated August 03, 2023 with respect to submission of the Company's Financial Results for the quarter ended June 30, 2023 in a Machine-Readable and searchable Form.

Please find enclosed herewith, copy of the Unaudited Standalone & Consolidated Financial Results of the Company for the quarter ended June 30, 2023, approved by the Board of Directors in their Meeting held on August 02, 2023, along with the Limited Review Report thereon in a Machine-Readable and searchable Form.

Please note that no alterations have been made to the Financial Results attached herewith; they remain identical to the ones previously submitted.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully

For **Metropolis Healthcare Limited**

Neha Shah
Interim Company Secretary
& Compliance Officer
Membership No. A51465

Encl. a/a

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

BSR & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai – 400063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited standalone financial results of Metropolis Healthcare Limited for the quarter ended 30 June 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Metropolis Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Metropolis Healthcare Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2023 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2023 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **BSR & Co. LLP**

Chartered Accountants

Firm's Registration No.: 101248W/W-100022



Rajesh Mehra

Partner

Mumbai

02 August 2023

Membership No.: 103145

UDIN: 23103145BGXWXO5600

Metropolis Healthcare Limited

Registered and Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400030

CIN:L73100MH2000PLC192798

Tel. No.: 022 6258 2810

Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohinoor Mall, Vidyavihar (West), Mumbai - 400070



Statement of Standalone Financial Results for the quarter ended 30 June 2023

(Rs. in Lakhs)

| Sr. No. | Particulars | Quarter ended | | | Year ended |
|-----------|--|-----------------------------|----------------------------|-----------------------------|----------------------------|
| | | 30 June 2023 (Unaudited) | 31 March 2023 (Audited) | 30 June 2022 (Unaudited) | 31 March 2023 (Audited) |
| 1 | Income | | | | |
| | a) Revenue from operations | 25,629.34 | 26,440.55 | 25,702.05 | 106,604.07 |
| | b) Other income | 278.13 | 913.85 | 242.41 | 2,128.26 |
| | Total Income | 25,907.47 | 27,354.40 | 25,944.46 | 108,732.33 |
| 2 | Expenses | | | | |
| | a) Cost of material consumed | 5,279.38 | 5,355.35 | 5,729.41 | 23,554.58 |
| | b) Laboratory testing charges | 234.74 | 135.47 | 217.20 | 574.87 |
| | c) Employee benefits expense | 5,847.19 | 5,706.14 | 5,722.91 | 22,816.29 |
| | d) Finance costs | 582.51 | 630.42 | 750.23 | 2,669.18 |
| | e) Depreciation and amortisation expense | 1,998.64 | 2,223.16 | 2,037.28 | 8,495.60 |
| | f) Other expenses | 8,441.79 | 8,471.69 | 7,929.84 | 32,727.29 |
| | Total Expenses | 22,384.25 | 22,522.23 | 22,386.87 | 90,837.81 |
| 3 | Profit before tax (1) - (2) | 3,523.22 | 4,832.17 | 3,557.59 | 17,894.52 |
| 4 | Tax expenses | | | | |
| | Current tax | 947.20 | 1,051.26 | 941.76 | 4,500.05 |
| | Deferred tax expense/(income) | (37.31) | 5.56 | (176.94) | (241.78) |
| | Tax adjustments for earlier years | - | (217.53) | (44.78) | (258.48) |
| | Total tax expenses | 909.89 | 839.29 | 720.04 | 3,999.79 |
| 5 | Profit for the period/year (3) - (4) | 2,613.33 | 3,992.88 | 2,837.55 | 13,894.73 |
| 6 | Other comprehensive income | | | | |
| | Items that will not be reclassified subsequently to profit and loss (net of tax) | (40.93) | (27.36) | (20.38) | (163.72) |
| | Items that will be subsequently reclassified to profit and loss (net of tax) | - | - | - | - |
| | Other comprehensive income for the period /year (net of tax) | (40.93) | (27.36) | (20.38) | (163.72) |
| 7 | Total comprehensive income (5) + (6) | 2,572.40 | 3,965.52 | 2,817.17 | 13,731.01 |
| 8 | Paid-up equity share capital (face value - Rs. 2 per share) | 1,024.22 | 1,024.21 | 1,023.48 | 1,024.21 |
| 9 | Other equity | - | - | - | 92,577.43 |
| 10 | Earnings per share (Face value of Rs.2 each) basic- (Rs.)* | 5.10 | 7.80 | 5.54 | 27.14 |
| | Earnings per share (Face value of Rs.2 each) diluted - (Rs.)* | 5.09 | 7.78 | 5.52 | 27.05 |

(*not annualised for the quarters)

See accompanying notes to the unaudited standalone financial results



NOTES:

- 1 The standalone financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
- 2 The standalone financial results of the Company have been reviewed by the Audit Committee at their meeting held on 02 August 2023 and thereafter approved by the Board of Directors at their meeting held on 02 August 2023. The statutory auditors have issued an unmodified review report on the above standalone financial results.
- 3 The figures for the three months ended 31 March 2023 are arrived at as difference between audited figures in respect of the full financial year and unaudited published figures up to nine months ended 31 December 2022.
- 4 Disclosure of segment-wise information is not applicable, as pathology services is the Company's only business segment.
- 5 The Board of Directors of the Company, at their meeting held on 11 February 2022, accorded in-principle approval for the voluntary liquidation of Dr. Ganesan's Hitech Diagnostic Centre Private Limited ('Hitech'), a wholly owned subsidiary of the Company, to be carried out under the provisions of Insolvency and Bankruptcy Code, 2016. The Board of Directors of Hitech in their meeting dated 01 April 2022 and the members of Hitech in their Extra Ordinary General meeting held on 01 April 2022 have accorded their approval for consolidation of the business of Hitech through voluntary liquidation process Pursuant to the ongoing liquidation process, the liquidator of Hitech has transferred the entire business undertaking to the Company on a going concern basis on and with effect from 04 June 2022.
- 6 On 16 November 2022, the Income Tax department conducted searches at the premises of the Company and some of its subsidiaries. No assets of the Company or its subsidiaries were seized during this process. The Company has been providing from time to time the information and clarifications sought by the Income Tax authorities. Subsequently, including during the current quarter, the Company and some of its subsidiaries have received notices under sections 147 and 148 of the Income Tax Act, 1961, that provide for the reopening of past assessment proceedings. Presently, there is no demand, and accordingly, no adjustments have been made in the financial results.
- 7 On review of the pattern of consumption of the future economic benefits embodied in the assets, it was noted that there has been change in expected pattern of consumption of these benefits. Accordingly, with effect from 01 April 2023, the Company has changed its depreciation/amortization method to Straight Line method from Written down value method for various class of assets to reflect this change. Such a change has been accounted for as a change in an accounting estimate in accordance with Ind AS 8 "Accounting Policies, Change in Accounting Estimates and Errors". Had the Company continued the previous Written Down Value Method for charging depreciation on all class of assets, charge for depreciation/amortisation for the quarter ended 30 June 2023 and for future period would have been higher by Rs. 265.38 lakhs and Rs. 662.36 lakhs respectively and consequentially deferred tax charge on the same for the quarter ended 30 June 2023 and for future period would have been lower by Rs. 66.80 lakhs and Rs. 166.72 lakhs respectively.
- 8 The standalone financial results of the Company are available for investors at www.metropolisindia.com, www.nseindia.com and www.bseindia.com.

Metropolis Healthcare Limited



Ameera Shah
Managing Director
DIN: 00208095
Place: Mumbai
Date: 02 August 2023



B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai – 400063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited consolidated financial results of Metropolis Healthcare Limited for the quarter ended 30 June 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Metropolis Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Metropolis Healthcare Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2023 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2023 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Registered Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013



Limited Review Report (Continued)

Metropolis Healthcare Limited

7. We did not review the interim financial information of one (1) subsidiary included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs 323.80 lakhs, total net profit after tax (before consolidation adjustments) and total comprehensive income (before consolidation adjustments) of Rs. 48.97 lakhs, for the quarter ended 30 June 2023, as considered in the Statement. This interim financial information has been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.


8. The Statement includes the interim financial information of 7 (seven) subsidiaries which have not been reviewed, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 1,968.43 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 222.39 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 33.90 lakhs, for the quarter ended 30 June 2023, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.: 101248W/W-100022



Rajesh Mehra

Partner

Mumbai

02 August 2023

Membership No.: 103145

UDIN: 23103145BGXWXP5356

Limited Review Report (Continued)

Metropolis Healthcare Limited

Annexure I

List of entities included in unaudited consolidated financial results.

| Sr. No | Name of component | Relationship |
|--------|---|-------------------------|
| 1 | Metropolis Healthcare Limited | Parent |
| 1 | Ekopath Metropolis Lab Services Private Limited | Subsidiary |
| 2 | Amins Pathology Laboratory Private Limited | Wholly owned subsidiary |
| 3 | Metropolis Histoexpert Digital Services Private Limited | Wholly owned subsidiary |
| 4 | Centralab Healthcare Services Private Limited | Wholly owned subsidiary |
| 5 | Metropolis Healthcare (Mauritius) Limited | Wholly owned subsidiary |
| 6 | Metropolis Star Lab Kenya Limited | Wholly owned subsidiary |
| 7 | Metropolis Healthcare Ghana Limited | Wholly owned subsidiary |
| 8 | Metropolis Bramser Lab Services (Mtius) Limited | Wholly owned subsidiary |
| 9 | Metropolis Healthcare (Tanzania) Limited | Wholly owned subsidiary |
| 10 | Metropolis Healthcare Lanka Private Limited | Wholly owned subsidiary |
| 11 | Metropolis Healthcare Uganda Limited | Wholly owned subsidiary |



Metropolis Healthcare Limited

Registered and Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400030

CIN L73100MH2000PLC192798

Tel. No.: 022 6258 2810

Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohinoor Mall, Vidyavihar (West), Mumbai - 400070

Statement of Consolidated Financial Results for the quarter ended 30 June 2023

(Rs. in Lakhs)

| Sr. No. | Particulars | Quarter ended | | | Year ended |
|-----------|--|-----------------------------|----------------------------|-----------------------------|----------------------------|
| | | 30 June 2023 (Unaudited) | 31 March 2023 (Audited) | 30 June 2022 (Unaudited) | 31 March 2023 (Audited) |
| 1 | Income | | | | |
| | a) Revenue from operations | 27,709.11 | 28,254.60 | 27,985.86 | 1,14,821.02 |
| | b) Other income | 305.25 | 122.63 | 303.89 | 1,522.46 |
| | Total Income | 28,014.36 | 28,377.23 | 28,289.75 | 1,16,343.48 |
| 2 | Expenses | | | | |
| | a) Cost of material consumed | 5,695.94 | 5,950.71 | 6,145.37 | 25,326.40 |
| | b) Laboratory testing charges | 242.04 | 33.56 | 273.97 | 657.09 |
| | c) Employee benefits expense | 6,505.83 | 6,431.47 | 6,221.11 | 25,273.41 |
| | d) Finance costs | 598.06 | 617.45 | 752.85 | 2,680.15 |
| | e) Depreciation and amortisation expense | 2,082.05 | 2,343.46 | 2,117.32 | 8,921.56 |
| | f) Other expenses | 8,971.44 | 8,810.24 | 8,496.26 | 34,734.53 |
| | Total Expenses | 24,095.36 | 24,186.89 | 24,006.88 | 97,593.14 |
| 3 | Profit before tax (1) - (2) | 3,919.00 | 4,190.34 | 4,282.87 | 18,750.34 |
| 4 | Tax expenses | | | | |
| | Current tax | 1,107.95 | 1,143.75 | 1,160.82 | 5,127.43 |
| | Deferred tax expense/(income) | (109.24) | (84.78) | (189.66) | (458.09) |
| | Tax adjustments for earlier years | 22.24 | (217.53) | (44.70) | (258.40) |
| | Total tax expenses | 1,020.95 | 841.44 | 926.46 | 4,410.94 |
| 5 | Profit for the period / year (3) - (4) | 2,898.05 | 3,348.90 | 3,356.41 | 14,339.40 |
| 6 | Other comprehensive income | | | | |
| | Items that will not be reclassified subsequently to profit and loss (net of tax) | (40.93) | (27.52) | (20.38) | (164.58) |
| | Items that will be subsequently reclassified to profit and loss (net of tax) | (188.49) | (68.78) | 18.13 | 129.74 |
| | Other comprehensive income for the period /year (net of tax) | (229.42) | (96.30) | (2.25) | (34.84) |
| 7 | Total comprehensive income (5) + (6) | 2,668.63 | 3,252.60 | 3,354.16 | 14,304.56 |
| 8 | Profit attributable to: | | | | |
| | Owners of the Company | 2,879.60 | 3,335.52 | 3,339.74 | 14,288.26 |
| | Non-controlling interest | 18.45 | 13.38 | 16.67 | 51.14 |
| 9 | Other comprehensive income attributable to: | | | | |
| | Owners of the Company | (229.62) | (96.44) | (2.25) | (34.70) |
| | Non-controlling interest | 0.20 | 0.14 | - | (0.14) |
| 10 | Total comprehensive income attributable to: | | | | |
| | Owners of the Company | 2,649.98 | 3,239.09 | 3,337.49 | 14,253.56 |
| | Non-controlling interest | 18.65 | 13.51 | 16.67 | 51.00 |
| 11 | Paid-up equity share capital (face value - Rs. 2 per share) | 1,024.21 | 1,024.21 | 1,023.48 | 1,024.21 |
| 12 | Other equity (including Non-controlling interest) | | | | 97,799.02 |
| 13 | Earnings per share (Face value of Rs 2each) basic- (Rs.)* | 5.62 | 6.51 | 6.53 | 27.91 |
| | Earnings per share (Face value of Rs 2 each) diluted - (Rs.)* | 5.61 | 6.49 | 6.49 | 27.81 |

(*not annualised for the quarters)

See accompanying note to the unaudited consolidated financial results



NOTES:

- 1 Metropolis Healthcare Limited (the 'Company' or the 'Parent') and its subsidiaries (referred collectively as the 'Group') are primarily involved in providing pathology and related healthcare services.
- 2 The consolidated financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3 The consolidated financial results of the Company have been reviewed by the Audit Committee at their meeting held on 02 August 2023 and thereafter approved by the Board of Directors at their meeting held on 02 August 2023. The statutory auditors have issued unmodified review report on the above consolidated financial results.
- 4 The figures for the three months ended 31 March 2023 are arrived at as difference between audited figures in respect of the full financial year and unaudited published figures up to nine months ended 31 December 2022.
- 5 Disclosure of segment-wise information is not applicable, as pathology services is the Group's only business segment.
- 6 The Board of Directors of the Company, at their meeting held on 11 February 2022, accorded in-principle approval for the voluntary liquidation of Dr. Ganesan's Hitech Diagnostic Centre Private Limited ('Hitech'), a wholly owned subsidiary of the Company, to be carried out under the provisions of Insolvency and Bankruptcy Code, 2016. The Board of Directors of Hitech in their meeting dated 01 April 2022 and the members of Hitech in their Extra Ordinary General meeting held on 01 April 2022 have accorded their approval for consolidation of the business of Hitech through voluntary liquidation process. Pursuant to the ongoing liquidation process, the liquidator of Hitech has transferred the entire business undertaking to the Company on a going concern basis on and with effect from 04 June 2022.
- 7 On 16 November 2022, the Income Tax department conducted searches at the premises of the Company and some of its subsidiaries. No assets of the Company or its subsidiaries were seized during this process. The Company has been providing from time to time the information and clarifications sought by the Income Tax authorities. Subsequently, including during the current quarter, the Company and some of its subsidiaries have received notices under sections 147 and 148 of the Income Tax Act, 1961, that provide for the reopening of past assessment proceedings. Presently, there is no demand, and accordingly, no adjustments have been made in the financial results.
- 8 On review of the pattern of consumption of the future economic benefits embodied in the assets, it was noted that there has been change in expected pattern of consumption of these benefits. Accordingly, with effect from 01 April 2023, the Group has changed its depreciation/amortization method to Straight Line method from Written down value method for various class of assets to reflect this change. Such a change has been accounted for as a change in an accounting estimate in accordance with Ind AS 8 "Accounting Policies, Change in Accounting Estimates and Errors". Had the Group continued the previous Written Down Value Method for charging depreciation on all class of assets, charge for depreciation/amortisation for the quarter ended 30 June 2023 and for future period would have been higher by Rs. 273.26 lakhs and Rs. 687.57 lakhs respectively and consequentially deferred tax charge on the same for the quarter ended 30 June 2023 and for future period would have been lower by Rs. 68.78 lakhs and Rs. 173.06 lakhs respectively.
- 9 The results of the Group are available for investors at www.metropolisindia.com, www.nseindia.com and www.bseindia.com.

For Metropolis Healthcare Limited

Ameera Shah
Managing Director
DIN: 00208095
Place: Mumbai
Date: 02 August 2023

